ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• KRAS mutations are common drivers in non-small cell lung cancer (NSCLC).
• Targeting KRAS or its downstream pathways is crucial for NSCLC treatment.
• ERK3, an atypical mitogen-activated protein kinase (MAPK), has an unclear role in cancer.

Purpose of the Study:

• To investigate the role of ERK3 in KRAS-mediated NSCLC.
• To determine if ERK3 is a potential therapeutic target in KRAS-driven NSCLC.

Main Methods:

• Assessed ERK3 expression and activation in lung cancer patient samples.
• Utilized cell culture models of KRAS G12C-transformed human bronchial epithelial cells.
• Performed in vitro kinase assays and in vivo tumor growth studies in mouse models.
• Investigated the effect of ERK3 loss on anchorage-independent growth.

Main Results:

• ERK3 is highly expressed in lung cancers and activated by oncogenic KRAS.
• Phosphorylation of ERK3 at serine 189 is elevated in lung adenocarcinomas.
• Loss of ERK3 inhibits anchorage-independent growth of KRAS G12C cells.
• ERK3 kinase activity is required for KRAS-driven oncogenesis in vitro and in vivo.

Conclusions:

• ERK3 plays an obligatory role in the progression of KRAS-driven NSCLC.
• ERK3 kinase inhibitors represent a potential therapeutic strategy for KRAS G12C-mutated NSCLC.